The content on this site is intended for healthcare professionals only
Prof Ribas presents the findings of a phase III trial, which showed pembrolizumab to be preferable to ipilimumab in advanced melanoma, at a press conference at AACR 2015.
Read the news story for more or watch the interview for more.